Branding on the barricades
According to the plan, the seminar took place the next morning. Main participants were the employees of ‘Alexandra’ company (one of the Kirghizian leaders in the fashion clothing market), the representatives of the several large companies and media-agencies.
Gene Zarkin told the participants how to decrease the risk of wasting time and money while developing the brand how to create the brand that gives real results and also uncovered the secret of how should the commercial companies act in the period of political instability to by-pass the crisis that some goverments sometimes fail to avoid.
Zarkin and Partners
Ligovsky 10, office 3139, Saint-Petersburg, Russia
Yulia Kuznetsova, PR-manager
Saint-Petersburg's branding advertising agency "Zarkin and Partners" specializes in the development of branding strategies.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Branding on the barricades here
News-ID: 12823 • Views: 1681
More Releases from Zarkin and Partners
Hong Kong business elite takes interest in Russia
The fashion week in Hong-Kong takes place twice a year since 1994. Organized by the Council of Hong-Kong trade development this exhibition regularly has about 1500 companies as participants and attracts more than 25 000 visitors from all over the world. This year one of the forums on Hong-Kong Fashion Week was devoted to the possibilities of Russian market. On the 13th of July in the Hong-Kong exhibition centre there
Dispute at Product Placement in Prague
On the 18th of June in Prague Gene Zarkin held a seminar at the conference “Product Placement – new Era of Advertising”, which was organized by the international company MARCUSEVANS. Seminar on the topic of “How to minimize the risk of wasting time and money while making investments in product placement” caused such a huge discussion. Some part of the participants thought that maybe the technology, which Gene was telling
On the 15th of June in Kiev (Ukraine) Gene Zarkin by the invitation of the operating director of the VE Products Cosmetic Company Ashok Kumar held a seminar on branding in the contest of Thai manufacturers of cosmetics exhibition. This exhibition and the seminar were organized by the Export Department of the ministry of Commerce of Thailand. Participants of the exhibition expressed hope that the new technology of branding and
Russian leads branding seminars in USA
On the 26th of May in Houston (USA) Gene Zarkin held a seminar on the topic of “How to reduce the risk of wasting time and money while creating a brand”. Representatives of some American companies, presented on the seminar, at first, were really surprised that a Russian man tells about the marketing technology which was developed in USA. And they were even more surprised by novelty of the received
More Releases for Gene
Gene Therapy Market, by Gene Therapy Type Germline Gene Therapy and Somatic Gene …
Genes are composed of deoxyribonucleic acid (DNA), which contains essential information for producing proteins that are crucial for the optimal functioning of the body. Genetic disorder is the result of gene mutations in which proteins are made incorrectly. Gene therapy is intended to introduce healthy gene into damaged cells to counteract for abnormal genes or to make a protein of interest. Mutated gene causes missing of the important protein, with
Hemophilia Gene Therapy - A Pipeline Analysis Report
"The Report Hemophilia Gene Therapy - A Pipeline Analysis Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Hemophilia Gene Therapy: An insight Hemophilia is an inherited bleeding disorder. The gene responsible for hemophilia is present on the X chromosome and is inherited in a recessive manner. Hemophilia A, also called as factor VIII (FVIII) deficiency or classic hemophilia, is caused by missing
Gene Synthesis Market Size 2017-2022 OriGene, Gene Oracle, Genescript
e Global Gene Synthesis Market Research Report 2016 is a professional and in-depth study on the current state of the Gene Synthesis market. Annual estimates and forecasts are provided for the period 2017 through 2022. Also, a six-year historic analysis is provided for these markets. The Global market for Gene Synthesis is expected to reach about 410 million USD by 2022 from 200 million USD in 2017, registering a compounded
Gene Therapy Drug Pipeline Analysis
“Gene Therapy Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of multiple disease based upon Gene Therapy. Research report covers all the ongoing drug development in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight
Cancer Gene Therapy Market Analysis
The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant
Global Gene Synthesis Market Research Report 2017
Global Gene Synthesis Market Research Report 2016 is a professional and in-depth study on the current state of the Gene Synthesis market. Annual estimates and forecasts are provided for the period 2017 through 2022. Also, a six-year historic analysis is provided for these markets. The Global market for Gene Synthesis is expected to reach about 410 million USD by 2022 from 200 million USD in 2017, registering a compounded annual